Axelar Receives Financing For A Phase I/II Clinical Trial On Cancer Patients

Thu, Jun 12, 2008 08:00 CET

Stockholm 2008-06-12

Axelar AB has received financing to perform a Phase I/II clinical trial on cancer patients with the insulin-like growth factor-1 (IGF-1) receptor inhibitor AXL1717.

Documents & Links

wkr0006.pdf